This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
SELL NOW!
TheStreet Rating

10 Best Biotech Stocks for 2014

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology


Source: TheStreet Ratings

Best Investments for 2014

Biotechnology News

Activist investor Alex Denner is gaining an ally on Ariad's Board.,
9/19/14 12:05PM
On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.
9/16/14 1:04PM
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
9/16/14 9:48AM
Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high
9/15/14 10:19AM
NPS Pharmaceuticals shares are weak Monday following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on Friday.
9/15/14 9:32AM
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
9/12/14 9:43AM
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
9/11/14 2:20PM
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.
9/11/14 1:23PM
Language in the new Xtandi label should help Medivation and Astellas widen their market share lead over Johnson & Johnson's competing prostate cancer drug Zytiga.
9/10/14 3:37PM
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
9/8/14 8:48AM
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
9/8/14 7:00AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
9/5/14 8:55AM
Merck will sell the skin cancer drug under the brand name Keytruda.
9/4/14 2:36PM
Under the agreement, Calico and Abbvie will work together to discover and develop new drugs for age-related diseases, including neuro-degeneration and cancer.
9/3/14 1:19PM
With Ampion failure, Ampio's pipeline is worthless.
9/3/14 12:04PM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs